【摘要】 目的观察评价甲磺酸阿帕替尼治疗晚期恶性肿瘤的疗效与安全性。方法回顾性分析2015年1月至2017年12月,医院共采用甲磺酸阿帕替尼治疗晚期恶性肿瘤84例。使用甲磺酸阿帕替尼治疗晚期非小细胞肺癌32例,纳入观察组,按照年龄(±2)、性别、分期、术前KPS评分(±5)、收治时间(±6个月)一对一选择32例未使用甲磺酸阿帕替尼治疗的晚期非小细胞肺癌患者,纳入对照组,进行对比分析。结果 CR13.1%、PR41.7%、SD25.0%、PD20.2%,总缓解54.8%,总控制79.8%,进展时间8(4-15)个月、生存时间15(6-28)个月。阿帕替尼有关不良反应发生率100.0%,主要包括高血压、手足综合征、食欲减退、乏力、尿蛋白,其中54例出现严重的不良反应。观察组与对照组疗效差异无统计学意义(P>0.05)。观察组进展时间9(5-14)个月,高于对照组7(4-10)个月,差异有统计学意义(P<0.05)。观察组生存时间17(8-25)个月,对照组15(7-22)个月,差异无统计学意义(P>0.05)。结论甲磺酸阿帕替尼治疗晚期恶性肿瘤的疗效肯定,但因使用患者较少,可以延缓进展时间,但也存在不良反应,严重不良反应发生风险较高,需慎重使用,提高个体化使用水平。更多还原

【Abstract】 Objective To observe the curative effect and safety evaluation of apatinib mesylate in treatment of advanced malignant tumor. Methods Retrospective analysis of January 2015 to December 2017, hospitals with apatinib mesylate in treatment of advanced malignant tumor in 84 cases. The use of apatinib mesylate in treatment of advanced non-small cell lung cancer in 32 cases, included in the observation group, according to age(±2), gender, staging, preoperative KPS score(±5), admission time(±6 months) of 32 patients without the use of apatinib mesylate in treatment of advanced non small cell lung cancer patients, included in the control group, comparative analysis. Results CR13.1%, PR41.7%, SD25.0% and PD20.2% total remission rate 54.8%, total control rate 79.8%, progression time 8(4-15) months, and survival time 15(6-28) months. Apatinib related adverse reaction rate was 100.00%, mainly including hypertension, hand foot syndrome, loss of appetite, fatigue, urinary protein, including 54 cases of serious adverse reactions. There was no significant difference in the curative effect between the observation group and the control group(P> 0.05). The time of progression in the observation group was 9(5-14) months, which was higher than that in the control group[7(4-10) months], the difference was statistically significant(P< 0.05). The survival time in the observation group was 17(8-25)months, the control group was 15(7-22)months, there was no significant difference(P> 0.05). Conclusion The curative effect of apatinib mesylate in treatment of advanced malignant tumor is affirmative, but due to the use of fewer patients, can delay the progress of time, but there are also adverse reactions, serious adverse reactions in high risk, should be cautious to use, improve the level of the individual use.更多还原